Nucleic Acid Nanostructure Spatial Organization for Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nucleic acid nanostructures lack precise control over immunostimulatory pathways and stoichiometry, limiting their ability to selectively modulate immune responses and induce specific innate immune activations.
Innovation Solution
Design and creation of nucleic acid nanostructures with defined geometric shapes and controlled organization of immunostimulatory agents, such as CpG motifs, to optimize inter-agent spacing, number, and spatial organization, enabling user-defined modulation of immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nucleic acid nanostructures are used to deliver immunostimulatory agents, then immune activation is enhanced, but precise control over immunostimulatory pathways and stoichiometry is lacking
Solution Approach 1:
The patent divides the nanostructure into distinct functional regions: a nucleic acid scaffold segment that provides structural organization, and separate immunostimulatory agent segments (such as CpG motifs) that are positioned at specific locations on the scaffold. This segmentation allows independent optimization and precise control of each component's function and spatial arrangement.
Solution Approach 2:
The patent implements local quality by varying the density, spacing, and distribution of immunostimulatory agents at different regions of the nanostructure. Specific areas are designed with higher concentrations of immunostimulatory motifs to create localized immune activation zones, while other regions maintain different compositions to modulate specific immune pathways selectively.
2Quantity of substance
If multiple immunostimulatory agents are incorporated into nanostructures, then immune response intensity increases, but control over inter-agent spacing and stoichiometry is limited
Solution Approach 1:
The patent transitions from one-dimensional linear arrangements to three-dimensional spatial organization of immunostimulatory agents on the nanostructure surface. By utilizing the three-dimensional space of the scaffold, the patent can precisely control inter-agent spacing in multiple dimensions, positioning agents at specific radial distances and angular orientations from the center.
Solution Approach 2:
The patent employs dynamic assembly processes where the final spatial arrangement of immunostimulatory agents is determined by controlled self-assembly or programmable positioning mechanisms. This allows the system to achieve precise stoichiometry and spacing through thermodynamic or kinetic control during formation, rather than requiring pre-positioning of each agent.
3Manufacturing precision
If defined geometric shapes are used for nanostructures, then spatial organization of immunostimulatory agents is improved, but device complexity increases
Solution Approach 1:
The patent designs universal nucleic acid scaffold geometries (such as icosahedral, cubic, or spherical shapes) that can accommodate various types and numbers of immunostimulatory agents through standardized attachment sites. These universal geometries serve multiple functions: providing structural stability, enabling predictable spatial arrangement, and allowing flexible functionalization with different immunostimulatory payloads without requiring redesign of the core geometry.
Data Source
AI summary
Compositions containing a nucleic acid nanostructure having a desired geometric shape and immunostimulatory agent(s) bound to its surface are provided. The nanostructures can be, for example, in the form of a 6-helix bundle, or icosahedron, or a pentagonal bipyramid. The nanostructure design allows for control of the relative position and/or stoichiometry of the immunostimulatory agent(s) bound to its surface. The immunostimulatory agent(s) displayed on the nanostructure surface are arranged with the preferred number, spacing, and 3D organization to elicit a robust immune response. The displayed antigen can be a TLR agonist, such as a TLR9 agonist. The immunostimulatory compositions may thus be useful as immunogens, vaccines, adjuvants, and the like. Methods of inducing immune responses, and for targeted induction of TLR activation are also provided.